Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice

Genetic and biochemical abnormalities associated with alpha-synuclein are implicated in the etiology of Parkinson's disease (PD). In this study, altered locomotor behavior linked to the expression of mutant or wildtype human alpha-synuclein was investigated. A53T alpha-synuclein transgenic (A53T-tg) mice exhibited normal activity at 5 months of age; however, by 7 months, they developed marked hyperactivity that remained evident until 19 months. By contrast, mice expressing human wildtype or A30P mutant alpha-synuclein showed no locomotor alterations. Hyperactivity in A53T-tg mice was reversed by the D1 receptor antagonist SCH 23390. Furthermore, A53T-tg mice were supersensitive to the D1 receptor agonist SKF 81297 but not to the serotonin1B receptor agonist RU 24969. Hyperactivity in A53T-tg mice was also associated with increased D1 receptor expression in the substantia nigra and decreased dopamine transporter expression in the nucleus accumbens and striatum. Finally, striatal dopamine uptake measured by high-speed chronoamperometry was reduced by 40% in A53T-tg mice. Thus, expression of A53T mutant human alpha-synuclein in mice results in adult-onset hyperactivity associated with D1 receptor and dopamine transporter-mediated alterations in dopamine neurotransmission.

[1]  J. Aceves,et al.  D-1 receptor mediated modulation of the release of γ-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  E. Abercrombie,et al.  Amphetamine‐induced release of dendritic dopamine in substantia nigra pars reticulata: D1‐mediated behavioral and electrophysiological effects , 1996, Synapse.

[3]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[4]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[5]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[6]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[7]  A. Sidhu,et al.  Attenuation of dopamine transporter activity by α-synuclein , 2003, Neuroscience Letters.

[8]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[10]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[11]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. O'Callaghan.  The astrocyte response to neural injury: a review and reconsideration of key features , 2002 .

[13]  J. Trojanowski.  Tauists, Baptists, Syners, Apostates, and new data , 2002, Annals of neurology.

[14]  F. Bloom,et al.  Neuroscience of Addiction , 1998, Neuron.

[15]  M. Savasta,et al.  Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390 , 1986, Brain Research.

[16]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[17]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[18]  Christine E. Hyde,et al.  Similar properties of fetal and adult amine transporters in the rat brain , 1994, Brain Research.

[19]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[20]  C. Altar,et al.  Topography of substantia nigra innervation by D1 receptor-containing striatal neurons , 1987, Brain Research.

[21]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  J. Salamone,et al.  Interactions between dopamine D1 receptors and γ-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies , 2001, Psychopharmacology.

[23]  M A Geyer,et al.  Prepulse Inhibition Deficits and Perseverative Motor Patterns in Dopamine Transporter Knock-Out Mice: Differential Effects of D1 and D2 Receptor Antagonists , 2001, The Journal of Neuroscience.

[24]  M. Starr,et al.  Differential behavioural interactions between the dopamine D-1 antagonist SCH 23390 and the dopamine D-2 antagonists metoclopramide and sulpiride in nonhabituated mice , 1990, Pharmacology Biochemistry and Behavior.

[25]  Ted M. Dawson,et al.  Animal Models of PD Pieces of the Same Puzzle? , 2002, Neuron.

[26]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[27]  G. Gerhardt.  Rapid Chronocoulometric Measurements of Norepinephrine Overflow and Clearance in CNS Tissues , 1995 .

[28]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[29]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[30]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[31]  R. Hen,et al.  Hyperactivity and impaired response habituation in hyperdopaminergic mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Georg Auburger,et al.  Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation , 2003, Molecular and Cellular Neuroscience.

[33]  C. V. Hartesveldt,et al.  Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats , 1993, Pharmacology Biochemistry and Behavior.

[34]  R. Beninger,et al.  The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats , 1985, Pharmacology Biochemistry and Behavior.

[35]  G. Gerhardt,et al.  In Vivo Electrochemical Studies of Dopamine Clearance in the Rat Substantia Nigra: Effects of Locally Applied Uptake Inhibitors and Unilateral 6‐Hydroxydopamine Lesions , 1998, Journal of neurochemistry.

[36]  M. Geyer,et al.  Serotonin1B Receptor Activation Mimics Behavioral Effects of Presynaptic Serotonin Release , 1993, Neuropsychopharmacology.

[37]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[38]  Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice. , 2005, Analytical chemistry.

[39]  R. Krüger,et al.  Familial parkinsonism with synuclein pathology , 2001, Neurology.

[40]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[41]  Donald C. Cooper,et al.  Loss of autoreceptor functions in mice lacking the dopamine transporter , 1999, Nature Neuroscience.

[42]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[43]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[44]  J. Salamone,et al.  Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat , 2001, Psychopharmacology.

[45]  George R. Uhl,et al.  Drug addiction: Knockout mice and dirty drugs , 1996, Current Biology.

[46]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[47]  M. Starr,et al.  Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse Implications for the roles of D1 and D2 receptors , 1986, Neuropharmacology.

[48]  S. Cheetham,et al.  Evidence that RU 24969‐induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5‐HT1B receptor , 1993, British journal of pharmacology.

[49]  Georg Auburger,et al.  Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background , 2005, Neurobiology of Aging.